Zacks Small Cap Issues Positive Outlook for MetaVia Earnings

MetaVia Inc. (NASDAQ:MTVA) – Research analysts at Zacks Small Cap raised their Q3 2025 earnings per share estimates for MetaVia in a note issued to investors on Wednesday, August 13th. Zacks Small Cap analyst D. Bautz now forecasts that the company will post earnings per share of ($0.22) for the quarter, up from their prior estimate of ($0.31). The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share. Zacks Small Cap also issued estimates for MetaVia’s Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.12) EPS.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.06.

Separately, Maxim Group reduced their price target on MetaVia from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, May 19th.

MetaVia Price Performance

Shares of NASDAQ MTVA opened at $0.64 on Monday. The stock has a 50 day moving average price of $0.67 and a 200 day moving average price of $1.03. MetaVia has a 52 week low of $0.56 and a 52 week high of $4.32.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.